Generic Name and Formulations:
Vancomycin (as HCl) 125mg, 250mg; caps.
Indications for VANCOCIN:
Enterocolitis due to S. aureus. Antibiotic-associated pseudomembranous colitis due to C. difficile.
≥18yrs: 500mg–2g per day in 3–4 divided doses for 7–10 days. C. difficile-associated diarrhea: 125mg 4 times a day for 10 days.
40mg/kg per day in 3–4 divided doses for 7–10 days; max 2g/day.
Renal insufficiency and/or colitis. Inflammatory bowel disorders. Underlying hearing loss. Monitor hearing, blood, renal function. Consider monitoring vancomycin serum concentrations. Elderly. Pregnancy (Cat.B). Nursing mothers: not recommended.
Monitor with aminoglycosides, other neurotoxic, nephrotoxic, or ototoxic drugs.
Nausea, abdominal pain, hypokalemia, drug fever, urticaria, rash (may be serious, eg, Stevens-Johnson syndrome), ototoxicity, nephrotoxicity, eosinophilia, anaphylaxis, superinfection, blood dyscrasias; rare: interstitial nephritis, vertigo.
Endocrinology Advisor Articles
- Higher BUN May Increase Risk for Incident Diabetes
- Efficacy of Novel GLP-1 Receptor Agonist Drug Device Examined
- Takeout Food May Increase Adverse Health Consequences in Children
- Nonhormonal Options Available for Menopause Symptom Relief
- Plasma Volume Changes Mediate Risk of CV Mortality With Empagliflozin
- New Consensus Recommendations on Use of Continuous Glucose Monitoring
- Does Genetic Susceptibility Lead to Late-Onset Type 1 Diabetes?
- Clinical Outcomes in T2D: Low-Carbohydrate vs Calorie-Restricted Diet
- New Continuous Glucose Monitoring System Now Available for Medicare Patients
- Text Message-Delivered Interventions Effective for Weight Management
- Effect of Intra-Articular Depot Betamethasone on Insulin Resistance in T2D
- Gastric Bypass vs Sleeve Gastrectomy Outcomes in Morbid Obesity
- Acute Kidney Injury Increases Risk for Postdischarge Hypoglycemia in Diabetes
- Novel Deep Learning System May Help Identify Diabetic Retinopathy
- Trends in CVD, Risk Factors, and Medications in Children With T1D